<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK100826" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK100826/" /><meta name="ncbi_pagename" content="Erythropoietic Protoporphyria, Autosomal Recessive - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Erythropoietic Protoporphyria, Autosomal Recessive - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Erythropoietic Protoporphyria, Autosomal Recessive" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/09/07" /><meta name="citation_author" content="Manisha Balwani" /><meta name="citation_author" content="Joseph Bloomer" /><meta name="citation_author" content="Robert Desnick" /><meta name="citation_author" content="Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network" /><meta name="citation_pmid" content="23016163" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK100826/" /><meta name="citation_keywords" content="Ferrochelatase, mitochondrial" /><meta name="citation_keywords" content="FECH" /><meta name="citation_keywords" content="Erythropoietic Protoporphyria, Autosomal Recessive" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Erythropoietic Protoporphyria, Autosomal Recessive" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Manisha Balwani" /><meta name="DC.Contributor" content="Joseph Bloomer" /><meta name="DC.Contributor" content="Robert Desnick" /><meta name="DC.Contributor" content="Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network" /><meta name="DC.Date" content="2017/09/07" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK100826/" /><meta name="description" content="Erythropoietic protoporphyria (EPP) is characterized by cutaneous photosensitivity (usually beginning in infancy or childhood) that results in tingling, burning, pain, and itching within 30 minutes after exposure to sun or ultraviolet light and may be accompanied by swelling and redness. Symptoms (which may seem out of proportion to the visible skin lesions) may persist for hours or days after the initial phototoxic reaction. Photosensitivity remains for life. Multiple episodes of acute photosensitivity may lead to chronic changes of sun-exposed skin (lichenification, leathery pseudovesicles, grooving around the lips) and loss of lunulae of the nails. Approximately 20%-30% of individuals with EPP have some degree of liver dysfunction, which is typically mild with slight elevations of the liver enzymes. Up to 5% may develop more advanced liver disease which may be accompanied by motor neuropathy similar to that seen in the acute porphyrias." /><meta name="og:title" content="Erythropoietic Protoporphyria, Autosomal Recessive" /><meta name="og:type" content="book" /><meta name="og:description" content="Erythropoietic protoporphyria (EPP) is characterized by cutaneous photosensitivity (usually beginning in infancy or childhood) that results in tingling, burning, pain, and itching within 30 minutes after exposure to sun or ultraviolet light and may be accompanied by swelling and redness. Symptoms (which may seem out of proportion to the visible skin lesions) may persist for hours or days after the initial phototoxic reaction. Photosensitivity remains for life. Multiple episodes of acute photosensitivity may lead to chronic changes of sun-exposed skin (lichenification, leathery pseudovesicles, grooving around the lips) and loss of lunulae of the nails. Approximately 20%-30% of individuals with EPP have some degree of liver dysfunction, which is typically mild with slight elevations of the liver enzymes. Up to 5% may develop more advanced liver disease which may be accompanied by motor neuropathy similar to that seen in the acute porphyrias." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK100826/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/epp-ar/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK100826/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE882999E0412F910000000000DA0056.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK100826_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK100826_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/ea2/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/tef-ov/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK100826_"><span class="title" itemprop="name">Erythropoietic Protoporphyria, Autosomal Recessive</span></h1><p class="contrib-group"><span itemprop="author">Manisha Balwani</span>, MD, MS, <span itemprop="author">Joseph Bloomer</span>, MD, <span itemprop="author">Robert Desnick</span>, MD, PhD, FACMG; <span itemprop="author">Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network</span>.</p><a data-jig="ncbitoggler" href="#__NBK100826_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK100826_ai__"><div class="contrib half_rhythm"><span itemprop="author">Manisha Balwani</span>, MD, MS<div class="affiliation small">Icahn School of Medicine at Mount Sinai<br />New York, New York<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.mssm@inawlab.ahsinam" class="oemail">ude.mssm@inawlab.ahsinam</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Joseph Bloomer</span>, MD<div class="affiliation small">University of Alabama at Birmingham<br />Birmingham, Alabama<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.bau@remoolbj" class="oemail">ude.bau@remoolbj</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Robert Desnick</span>, MD, PhD, FACMG<div class="affiliation small">Icahn School of Medicine at Mount Sinai<br />New York, New York<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.mssm@kcinsed.trebor" class="oemail">ude.mssm@kcinsed.trebor</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network</span><sup><a href="#epp-ar.Tb.an4" class="bk_pop">*</a></sup></div></div><p class="small">Initial Posting: <span itemprop="datePublished">September 27, 2012</span>; Last Update: <span itemprop="dateModified">September 7, 2017</span>.</p><p><em>Estimated reading time: 23 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="epp-ar.Summary" itemprop="description"><h2 id="_epp-ar_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Erythropoietic protoporphyria (EPP) is characterized by cutaneous photosensitivity (usually beginning in infancy or childhood) that results in tingling, burning, pain, and itching within 30 minutes after exposure to sun or ultraviolet light and may be accompanied by swelling and redness. Symptoms (which may seem out of proportion to the visible skin lesions) may persist for hours or days after the initial phototoxic reaction. Photosensitivity remains for life. Multiple episodes of acute photosensitivity may lead to chronic changes of sun-exposed skin (lichenification, leathery pseudovesicles, grooving around the lips) and loss of lunulae of the nails. Approximately 20%-30% of individuals with EPP have some degree of liver dysfunction, which is typically mild with slight elevations of the liver enzymes. Up to 5% may develop more advanced liver disease which may be accompanied by motor neuropathy similar to that seen in the acute porphyrias.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of EPP is established by detection of markedly increased free erythrocyte protoporphyrin and/or by the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>FECH</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Afamelanotide (Scenesse<sup>&#x000ae;</sup>), a synthetic &#x003b1;-melanocyte stimulating hormone analog was approved for treatment of EPP by the European Medicines Agency in 2014 and is awaiting approval in the US by the FDA. This medication increases pain-free sun exposure and has improved quality of life in those with EPP. The phototoxic pain is not responsive to narcotic analgesics. Current management centers on prevention of the painful attacks by avoidance of sun/light (including the long-wave ultraviolet light sunlight that passes through window glass) through use of protective clothing (e.g., long sleeves, gloves, wide-brimmed hats, protective tinted glass for cars and windows). Although topical sunscreens are typically not useful, some tanning products containing creams that cause increased pigmentation may be helpful.</p><p>Severe liver complications are difficult to treat: cholestyramine and other porphyrin absorbents (to interrupt the enterohepatic circulation of protoporphyrin and promote its fecal excretion) and plasmapheresis and intravenous hemin are sometimes beneficial. Liver transplantation may be required.</p><p><i>Prevention of primary manifestations.</i> Sun avoidance.</p><p><i>Prevention of secondary complications:</i> Vitamin D supplementation to prevent vitamin D insufficiency due to sun avoidance. Immunization for hepatitis A and B.</p><p><i>Surveillance:</i> Monitoring of: hepatic function every six to 12 months and hepatic imaging if cholelithiasis is suspected; erythrocyte protoporphyrin levels (free and zinc-chelated), hematologic indices, and iron profile annually; vitamin D 25-OH levels.</p><p><i>Agents/circumstances to avoid:</i> Avoid: sunlight and UV light; for those with hepatic dysfunction, drugs that may induce cholestasis (e.g., estrogens). For those with cholestatic liver failure, use of protective filters for artificial lights in the operating room to avoid phototoxic damage.</p><p><i>Evaluation of relatives at risk:</i> If both <i>FECH</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, at-risk relatives can be tested as newborns or infants so that those with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants can benefit from early intervention (sun protection) and future monitoring for signs of liver dysfunction.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>EPP is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. In about 96% of cases an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual inherits a <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> <i>FECH</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> from one parent and a low-expression <i>FECH</i> allele from the other parent. In about 4% of cases, an affected individual has two loss-of-function <i>FECH</i> alleles. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Heterozygotes (carriers) and individuals who inherit two low-expression alleles are asymptomatic. Carrier testing for at-risk family members and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family have been identified.</p></div></div><div id="epp-ar.Diagnosis"><h2 id="_epp-ar_Diagnosis_">Diagnosis</h2><div id="epp-ar.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Erythropoietic protoporphyria (EPP) <b>should be suspected</b> in individuals with the following clinical features and suggestive laboratory findings.</p><p><b>Clinical features</b></p><ul><li class="half_rhythm"><div>Cutaneous photosensitivity, usually beginning in childhood</div></li><li class="half_rhythm"><div>Burning, tingling, and itching (the most common findings); may occur within minutes of sun/light exposure, followed later by erythema and swelling</div></li><li class="half_rhythm"><div>Burning, itching, and intense pain; may occur without obvious skin damage</div></li><li class="half_rhythm"><div>Absent or sparse blisters and bullae (Note: The absence of skin damage [e.g., scarring], vesicles, and bullae often make it difficult to establish the diagnosis.)</div></li><li class="half_rhythm"><div>Hepatic dysfunction; may occur in 20%-30% of individuals (~2%-5% have severe liver disease that may be life threatening, necessitating liver transplantation.)</div></li></ul><p><b>Suggestive biochemical laboratory findings.</b> Detection of markedly increased free erythrocyte protoporphyrin is the most sensitive and specific biochemical diagnostic test for EPP (see <a class="figpopup" href="/books/NBK100826/table/epp-ar.T.biochemical_characteristics_of/?report=objectonly" target="object" rid-figpopup="figepparTbiochemicalcharacteristicsof" rid-ob="figobepparTbiochemicalcharacteristicsof">Table 1</a>).</p><p>Note: It is important to evaluate by using an assay that distinguishes free protoporphyrin from zinc-chelated protoporphyrin, as several other conditions may lead to elevation of erythrocyte protoporphyrins (see <a class="figpopup" href="/books/NBK100826/table/epp-ar.T.biochemical_characteristics_of/?report=objectonly" target="object" rid-figpopup="figepparTbiochemicalcharacteristicsof" rid-ob="figobepparTbiochemicalcharacteristicsof">Table 1</a> footnote 5).</p><div id="epp-ar.T.biochemical_characteristics_of" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Biochemical Characteristics of Erythropoietic Protoporphyria (EPP)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK100826/table/epp-ar.T.biochemical_characteristics_of/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epp-ar.T.biochemical_characteristics_of_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Deficient Enzyme</th><th id="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Enzyme Activity</th><th id="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Erythrocytes</th><th id="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Urine</th><th id="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Stool</th><th id="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Other</th></tr></thead><tbody><tr><td headers="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ferrochelatase&#x000a0;<sup>1</sup></td><td headers="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~10%-30% of normal&#x000a0;<sup>2</sup></td><td headers="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Free protoporphyrin: increased&#x000a0;<sup>3,&#x000a0;4,&#x000a0;5,&#x000a0;6</sup></td><td headers="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Protoporphyrins: normal</td><td headers="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Protoporphyrin: normal or increased</td><td headers="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Plasma porphyrins: increased&#x000a0;<sup>7,&#x000a0;8</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="epp-ar.TF.1.1"><p class="no_margin">Deficient activity of ferrochelatase (EC 4.99.1.1), encoded by <i>FECH</i>, leads to the systemic accumulation of free protoporphyrin and a markedly lesser amount of zinc-chelated protoporphyrin, particularly in erythroid and hepatic cells.</p></div></dd><dt>2. </dt><dd><div id="epp-ar.TF.1.2"><p class="no_margin">The assay for the enzyme ferrochelatase is not widely available and is not used for diagnostic purposes.</p></div></dd><dt>3. </dt><dd><div id="epp-ar.TF.1.3"><p class="no_margin">In EPP, free protoporphyrin levels are elevated significantly as compared to zinc-chelated protoporphyrin.</p></div></dd><dt>4. </dt><dd><div id="epp-ar.TF.1.4"><p class="no_margin">Many assays for erythrocyte protoporphyrin or &#x0201c;free erythrocyte protoporphyrin&#x0201d; measure both zinc-chelated protoporphyrin and free protoporphyrin. Free protoporphyrin is distinguished from zinc-chelated protoporphyrin by ethanol extraction or HPLC.</p></div></dd><dt>5. </dt><dd><div id="epp-ar.TF.1.5"><p class="no_margin">Protoporphyrins (usually zinc-chelated protoporphyrin) are also increased in lead poisoning, iron deficiency, anemia of chronic disease, and various hemolytic disorders, as well as in those porphyrias caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants (e.g., harderoporphyria), which are more severe than the acute <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> porphyrias (e.g., <a href="/books/n/gene/hcp/">hereditary coproporphyria</a>) caused by a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> variant of the same <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (e.g., <i>CPOX</i>).</p></div></dd><dt>6. </dt><dd><div id="epp-ar.TF.1.6"><p class="no_margin">In <a href="/books/n/gene/epp-xl/">X-linked protoporphyria</a> (XLP), resulting from pathogenic <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> variants in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11 of <i>ALAS2</i>, both free and zinc-chelated protoporphyrins are increased (see <a href="#epp-ar.Differential_Diagnosis">Differential Diagnosis</a>).</p></div></dd><dt>7. </dt><dd><div id="epp-ar.TF.1.7"><p class="no_margin">Plasma porphyrins of the III-isomer series are usually increased.</p></div></dd><dt>8. </dt><dd><div id="epp-ar.TF.1.8"><p class="no_margin">Plasma total porphyrins are increased in porphyrias with cutaneous manifestations including EPP. If plasma porphyrins are increased, the fluorescence emission spectrum of plasma porphyrins at neutral pH can be characteristic and can distinguish EPP from other porphyrias. The emission maximum in EPP occurs at 632-634 nm.</p></div></dd></dl></div></div></div></div><div id="epp-ar.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of EPP <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> who has markedly increased free erythrocyte protoporphyrin and/or by the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>FECH</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK100826/table/epp-ar.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figepparTmoleculargenetictestingused" rid-ob="figobepparTmoleculargenetictestingused">Table 2</a>).</p><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>FECH</i> is performed first, and followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>FECH</i> and other genes of interest (see <a href="#epp-ar.Differential_Diagnosis">Differential Diagnosis</a>) may be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered if single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that includes <i>FECH</i>) fails to confirm a diagnosis in an individual with features of EPP and a significantly elevated erythrocyte protoporphyrin level. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation). For an introduction to comprehensive genomic testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="epp-ar.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Erythropoietic Protoporphyria</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK100826/table/epp-ar.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epp-ar.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_epp-ar.T.molecular_genetic_testing_used_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_epp-ar.T.molecular_genetic_testing_used_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_epp-ar.T.molecular_genetic_testing_used_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_epp-ar.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>FECH</i></td><td headers="hd_h_epp-ar.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_epp-ar.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~91.5%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_epp-ar.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_epp-ar.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~8.5%&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_epp-ar.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>7</sup></td><td headers="hd_h_epp-ar.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_epp-ar.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="epp-ar.TF.2.1"><p class="no_margin">See <a href="/books/NBK100826/#epp-ar.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="epp-ar.TF.2.2"><p class="no_margin">See <a href="#epp-ar.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="epp-ar.TF.2.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="epp-ar.TF.2.4"><p class="no_margin">In addition to flanking <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> regions, <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> must include deep regions of at least some introns to detect <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> or other <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> alleles (in particular, the common <a class="figpopup" href="/books/NBK100826/table/epp-ar.T.selected_fech_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figepparTselectedfechpathogenicvarian" rid-ob="figobepparTselectedfechpathogenicvarian">c.315-48T&#x0003e;C</a> variant).</p></div></dd><dt>5. </dt><dd><div id="epp-ar.TF.2.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods that may be used include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="epp-ar.TF.2.6"><p class="no_margin"><a class="bk_pop" href="#epp-ar.REF.whatley.2007.2790">Whatley et al [2007]</a>, <a class="bk_pop" href="#epp-ar.REF.balwani.2013.26">Balwani et al [2013]</a></p></div></dd><dt>7. </dt><dd><div id="epp-ar.TF.2.7"><p class="no_margin">In males the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of EPP is clinically indistinguishable from that of <a href="/books/n/gene/epp-xl/">X-linked protoporphyria</a> (XLP). Based on reported and unreported information, individuals with an EPP or XLP phenotype and with significantly elevated erythrocyte protoporphyrin levels who do not have <i>FECH</i> or <i>ALAS2</i> pathogenic variants have (rarely) been noted in the European Union [<a class="bk_pop" href="#epp-ar.REF.whatley.2010.642">Whatley et al 2010</a>] as well as in the US (9 individuals) [<a class="bk_pop" href="#epp-ar.REF.balwani.2017.789">Balwani et al 2017</a>].</p></div></dd></dl></div></div></div><p>Note: Individuals with EPP have pathogenic variants in both <i>FECH</i> alleles.</p><ul><li class="half_rhythm"><div class="half_rhythm">About 96% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are compound heterozygotes for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> resulting in markedly decreased ferrochelatase activity and a second low-expression pathogenic variant (c.315-48T&#x0003e;C; also known as IVS3-48T&#x0003e;C) resulting in residual ferrochelatase activity.</div><div class="half_rhythm">In populations in which a low-expression <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is quite common (see <a href="#epp-ar.Prevalence">Prevalence</a>), the disorder may appear to be "pseudodominant" &#x02012; that is, an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> condition present in individuals in two or more generations of a family, thereby appearing to follow a dominant inheritance pattern. An example is the low-expression allele resulting from the cryptic <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variant <a class="figpopup" href="/books/NBK100826/table/epp-ar.T.selected_fech_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figepparTselectedfechpathogenicvarian" rid-ob="figobepparTselectedfechpathogenicvarian">c.315-48T&#x0003e;C</a> that has an <a class="def" href="/books/n/gene/glossary/def-item/allele-frequency/">allele frequency</a> of about 10% in healthy individuals of European descent [<a class="bk_pop" href="#epp-ar.REF.gouya.1999.2105">Gouya et al 1999</a>, <a class="bk_pop" href="#epp-ar.REF.gouya.2002.27">Gouya et al 2002</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">In about 4% of families with EPP, two pathogenic <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> <i>FECH</i> variants are inherited, resulting in very low levels of functional ferrochelatase [<a class="bk_pop" href="#epp-ar.REF.whatley.2010.642">Whatley et al 2010</a>].</div></li></ul></div></div><div id="epp-ar.Clinical_Characteristics"><h2 id="_epp-ar_Clinical_Characteristics_">Clinical Characteristics</h2><div id="epp-ar.Clinical_Description"><h3>Clinical Description</h3><p><b>Photosensitivity.</b> Onset of photosensitivity is typically in infancy or childhood (with the first exposure to sun) and the photosensitivity remains for life.</p><ul><li class="half_rhythm"><div>Most individuals with EPP develop acute cutaneous photosensitivity within 30 minutes after exposure to sun or ultraviolet light.</div></li><li class="half_rhythm"><div>Photosensitivity symptoms are provoked mainly by visible blue-violet light in the Soret band and to a lesser degree in the long-wave UV region.</div></li><li class="half_rhythm"><div>Affected individuals are also sensitive to sunlight that passes through window glass that does not block long-wave UVA or visible light.</div></li><li class="half_rhythm"><div>The initial symptoms reported are tingling, burning, and/or itching that may be accompanied by swelling and redness.</div></li><li class="half_rhythm"><div>Symptoms vary based on the intensity and duration of sun exposure; pain may be severe and refractory to narcotic analgesics, persisting for hours or days after the initial phototoxic reaction.</div></li><li class="half_rhythm"><div>Symptoms may seem out of proportion to the visible skin lesions.</div></li><li class="half_rhythm"><div>Pregnancy has been associated with decreased protoporphyrin levels and increased tolerance to sun exposure [<a class="bk_pop" href="#epp-ar.REF.anderson.2001">Anderson et al 2001</a>, <a class="bk_pop" href="#epp-ar.REF.wahlin.2011a.278">Wahlin et al 2011a</a>].</div></li></ul><p><b>Cutaneous manifestations.</b> Multiple episodes of acute photosensitivity may lead to chronic changes of sun-exposed skin (lichenification, leathery pseudovesicles, grooving around the lips) and loss of lunulae of the nails. The dorsum of the hands is most notably <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p><ul><li class="half_rhythm"><div>Severe scarring is rare, as are pigment changes, friability, and hirsutism.</div></li><li class="half_rhythm"><div>Blistering was reported in 26% of individuals in one large series [<a class="bk_pop" href="#epp-ar.REF.balwani.2017.789">Balwani et al 2017</a>].</div></li><li class="half_rhythm"><div>Palmar keratoderma has been observed in some individuals with two <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> <i>FECH</i> alleles (in contrast to one severe loss-of-function <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and the low-expression allele) [<a class="bk_pop" href="#epp-ar.REF.holme.2009.599">Holme et al 2009</a>, <a class="bk_pop" href="#epp-ar.REF.m_ndez.2009.1330">M&#x000e9;ndez et al 2009</a>, <a class="bk_pop" href="#epp-ar.REF.minder.2010.1349">Minder et al 2010</a>].</div></li></ul><p><b>Hepatobiliary manifestations.</b> Protoporphyrin is not excreted by the kidneys, but is taken up by the liver and excreted in the bile. Accumulated protoporphyrin in the bile can form stones, reduce bile flow, and damage the liver.</p><ul><li class="half_rhythm"><div>Protoporphyric liver disease may cause severe abdominal pain (especially in the right upper quadrant) and back pain.</div></li><li class="half_rhythm"><div>Gallstones composed in part of protoporphyrin may be symptomatic in individuals with EPP and need to be excluded as a cause of biliary obstruction in persons with hepatic decompensation.</div></li><li class="half_rhythm"><div>About 20%-30% of individuals with EPP have some degree of liver dysfunction.</div></li><li class="half_rhythm"><div>In most cases, the hepatic manifestations are mild with slight elevations of the liver enzymes.</div></li><li class="half_rhythm"><div>However, up to 5% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals may develop more advanced liver disease, most notably cholestatic liver failure. In most of these individuals, underlying liver cirrhosis is already present; however, some may present with rapidly progressive cholestatic liver failure.</div></li><li class="half_rhythm"><div>Life-threatening hepatic complications are preceded by increased levels of plasma and erythrocyte protoporphyrins, worsening hepatic function tests, increased photosensitivity, and increased deposition of protoporphyrins in hepatic cells and bile canaliculi.</div></li><li class="half_rhythm"><div>End-stage liver disease may be accompanied by motor neuropathy, similar to that seen in <a href="/books/n/gene/aip/">acute porphyrias</a>.</div></li><li class="half_rhythm"><div>Comorbid conditions including viral hepatitis, alcohol abuse, and use of oral contraceptives (which may impair hepatic function or protoporphyrin metabolism) may contribute to hepatic disease in some [<a class="bk_pop" href="#epp-ar.REF.mcguire.2005.1590">McGuire et al 2005</a>].</div></li><li class="half_rhythm"><div>The risk of liver disease appears to be related to higher protoporphyrin levels.</div></li></ul><p><b>Hematologic manifestations.</b> Anemia and abnormal iron metabolism can occur in EPP. Mild anemia with microcytosis and hypochromia or occasionally reticulocytosis can be seen; however, hemolysis is absent or mild.</p><p><b>Vitamin D deficiency.</b> Persons with EPP who avoid sun/light are at risk for vitamin D deficiency [<a class="bk_pop" href="#epp-ar.REF.holme.2008.211">Holme et al 2008</a>, <a class="bk_pop" href="#epp-ar.REF.spelt.2010.s1">Spelt et al 2010</a>, <a class="bk_pop" href="#epp-ar.REF.wahlin.2011a.278">Wahlin et al 2011a</a>].</p><p><b>Precipitating factors</b>. Unlike the acute hepatic porphyrias, the only known precipitating factor for EPP is sun/light.</p></div><div id="epp-ar.Pathophysiology"><h3>Pathophysiology</h3><p>The deficient activity (&#x0003c;30% of normal) of ferrochelatase results in EPP.</p><p>Bone marrow reticulocytes are thought to be the primary source of the accumulated protoporphyrin that is excreted in bile and feces. At times, the liver may be an important source of excess protoporphyrin, but measuring its contribution relative to that of the erythron has not been possible.</p><p>Most of the excess protoporphyrin in circulating erythrocytes is found in a small percentage of cells, and the rate of protoporphyrin leakage from these cells is proportional to their protoporphyrin content. Erythrocyte protoporphyrin in EPP is more than 90% free and not complexed with zinc. The content of free protoporphyrin in these cells declines much more rapidly when red cells age than it does in conditions in which erythrocyte zinc-chelated protoporphyrin is increased. Moreover, ultraviolet light may cause free protoporphyrin to be released from the red cell even without disruption of the red cell membrane. In this manner, free protoporphyrin may then diffuse into the plasma (where it is bound to albumin) and be taken up by the endothelium of blood vessels.</p><p>The skin of persons with EPP is maximally sensitive to visible blue-violet light near 400 nm, which corresponds to the so-called Soret band (the narrow peak absorption maximum that is characteristic for protoporphyrin and other porphyrins). When porphyrins absorb light they enter an excited energy state. This energy is presumably released as fluorescence and by formation of singlet oxygen and other oxygen radicals that can produce tissue and vessel damage. This may involve lipid peroxidation, oxidation of amino acids, and cross-linking of proteins in cell membranes.</p><p>Photoactivation of the complement system and release of histamine, kinins, and chemotactic factors may mediate skin damage. Histologic changes occur predominantly in the upper dermis and include deposition of amorphous material containing immunoglobulin, complement components, glycoproteins, acid glycosaminoglycans, and lipids around blood vessels. Damage to capillary endothelial cells in the upper dermis has been demonstrated immediately after light exposure in this disease [<a class="bk_pop" href="#epp-ar.REF.schneideryin.2000.719">Schneider-Yin et al 2000</a>].</p><p>As noted, individuals with EPP appear to be predisposed to developing gallstones that are fluorescent and contain large quantities of protoporphyrin. In one series, approximately 22% of individuals with EPP had a known history of gallstones [<a class="bk_pop" href="#epp-ar.REF.balwani.2017.789">Balwani et al 2017</a>]. This and other hepatobiliary complications relate to uptake and excretion of protoporphyrin by the liver [<a class="bk_pop" href="#epp-ar.REF.bloomer.1988.402">Bloomer 1988</a>]. This dicarboxyl porphyrin is not soluble in aqueous solution and is therefore not excreted in urine.</p><p>Long-term observations of patients with protoporphyria generally show little change in protoporphyrin levels in erythrocytes, plasma, and feces. On the other hand, severe hepatic complications, when they do occur, often follow increasing accumulation of protoporphyrin in erythrocytes, plasma, and liver. Iron deficiency and factors that impair liver function sometimes contribute. Enterohepatic circulation of protoporphyrin may favor its return and retention in the liver, especially when liver function is impaired. Liver damage probably results at least in part from protoporphyrin accumulation itself, as this porphyrin is insoluble, tends to form crystalline structures in liver cells, can impair mitochondrial functions in liver cells, and can decrease hepatic bile formation and flow [<a class="bk_pop" href="#epp-ar.REF.bloomer.1988.402">Bloomer 1988</a>, <a class="bk_pop" href="#epp-ar.REF.anderson.2001">Anderson et al 2001</a>].</p></div><div id="epp-ar.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>About 96% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are compound heterozygotes for a <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variant that markedly decreases ferrochelatase (FECH) activity and a second low-expression <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> which also decreases the FECH activity by about 50%.</p><p>Persons with low residual activity may have a more severe clinical presentation. Palmar keratoderma was reported in persons with two <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> <i>FECH</i> variants [<a class="bk_pop" href="#epp-ar.REF.holme.2009.599">Holme et al 2009</a>, <a class="bk_pop" href="#epp-ar.REF.m_ndez.2009.1330">M&#x000e9;ndez et al 2009</a>, <a class="bk_pop" href="#epp-ar.REF.minder.2010.1349">Minder et al 2010</a>]. Some reports have indicated that <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> variants in <i>FECH</i> may be associated with liver complications [<a class="bk_pop" href="#epp-ar.REF.minder.2002.91">Minder et al 2002</a>],</p><p>Individuals with EPP with pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants have significantly lower median erythrocyte protoporphyrin levels than those with deletions or <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> or consensus <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants. The greater the level of erythrocyte protoporphyrin, the more likely that the patient will be more severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, characterized by decreased sun tolerance and increased risk of liver dysfunction [<a class="bk_pop" href="#epp-ar.REF.balwani.2017.789">Balwani et al 2017</a>].</p></div><div id="epp-ar.Penetrance"><h3>Penetrance</h3><p>EPP appears to be 100% penetrant when there are <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>FECH</i> <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants or compound heterozygosity for a <i>FECH</i> loss-of-function variant and a variant that causes low expression of the other <i>FECH</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a><i>.</i></p></div><div id="epp-ar.Nomenclature"><h3>Nomenclature</h3><p>Obsolete terms for EPP are: erythrohepatic protoporphyria, heme synthetase deficiency, and ferrochelatase deficiency</p></div><div id="epp-ar.Prevalence"><h3>Prevalence</h3><p>EPP is the third most common porphyria, with an estimated incidence of two to five in 1,000,000; it is the most common porphyria in children.</p><p>EPP is equally common in women and men. The prevalence ranges from 1:75,000 in the Netherlands (as the result of a <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a>) to 1:200,000 reported in Wales [<a class="bk_pop" href="#epp-ar.REF.holme.2006.574">Holme et al 2006</a>].</p><p>EPP has been described worldwide. The prevalence of EPP may vary based on the population <a class="def" href="/books/n/gene/glossary/def-item/allele-frequency/">allele frequency</a> of the low-expression <a class="figpopup" href="/books/NBK100826/table/epp-ar.T.selected_fech_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figepparTselectedfechpathogenicvarian" rid-ob="figobepparTselectedfechpathogenicvarian">c.315-48T&#x0003e;C</a> allele, which ranges from approximately 1%-3% in Africans to approximately 43% in Japanese.</p></div></div><div id="epp-ar.Genetically_Related_Allelic_Disor"><h2 id="_epp-ar_Genetically_Related_Allelic_Disor_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>FECH.</i></p></div><div id="epp-ar.Differential_Diagnosis"><h2 id="_epp-ar_Differential_Diagnosis_">Differential Diagnosis</h2><p>Other causes of the erythropoietic protoporphyria (EPP) <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> include the following.</p><p><b>Acquired causes</b></p><ul><li class="half_rhythm"><div>Polymorphous light eruption</div></li><li class="half_rhythm"><div>Solar urticaria</div></li><li class="half_rhythm"><div>Drug-induced photosensitivity</div></li></ul><p><b>Acquired late-onset EPP <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a></b> has been described in rare instances secondary to myelodysplastic syndrome caused by <a class="def" href="/books/n/gene/glossary/def-item/somatic-pathogenic-variant/">somatic pathogenic variant</a>(s) that decrease ferrochelatase activity, presumably a result of the <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> instability associated with myelodysplasia [<a class="bk_pop" href="#epp-ar.REF.aplin.2001.1647">Aplin et al 2001</a>, <a class="bk_pop" href="#epp-ar.REF.sarkany.2006.464">Sarkany et al 2006</a>, <a class="bk_pop" href="#epp-ar.REF.blagojevic.2010.743">Blagojevic et al 2010</a>].</p><p><a href="/books/n/gene/epp-xl/"><b>X-linked protoporphyria</b></a>
<b>(XLP)</b> (also known as EPP, <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a>) is caused by pathogenic <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> variants in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11 of <i>ALAS2</i> (the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding erythroid-specific 5-aminolevulinate synthase). In males the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is clinically indistinguishable from that of EPP caused by two <i>FECH</i> pathogenic variants; in female heterozygotes the phenotype is more variable, depending primarily on random <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> [<a class="bk_pop" href="#epp-ar.REF.brancaleoni.2016.20">Brancaleoni et al 2016</a>]. A higher percentage of persons with liver dysfunction have been reported with XLP [<a class="bk_pop" href="#epp-ar.REF.whatley.2008.408">Whatley et al 2008</a>].</p><p>Recent natural history studies showed that 37.5% of males with XLP and 22.2% of females with XLP had abnormal serum aminotransferases compared to 13.7% of individuals with EPP [<a class="bk_pop" href="#epp-ar.REF.balwani.2017.789">Balwani et al 2017</a>].</p><p>In XLP, the ratio of free protoporphyrin to zinc-chelated protoporphyrin may range from 90:30 to 50:50 (<a class="figpopup" href="/books/NBK100826/table/epp-ar.T.biochemical_characteristics_of_1/?report=objectonly" target="object" rid-figpopup="figepparTbiochemicalcharacteristicsof1" rid-ob="figobepparTbiochemicalcharacteristicsof1">Table 3</a>). Plasma levels of protoporphyrin are elevated.</p><div id="epp-ar.T.biochemical_characteristics_of_1" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Biochemical Characteristics of X-Linked Protoporphyria (XLP)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK100826/table/epp-ar.T.biochemical_characteristics_of_1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epp-ar.T.biochemical_characteristics_of_1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Enzyme</th><th id="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Enzyme Activity</th><th id="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Erythrocytes</th><th id="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Urine</th><th id="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Stool</th><th id="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Other</th></tr></thead><tbody><tr><td headers="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Erythroid-specific 5-aminolevulinate synthase</td><td headers="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;100%&#x000a0;<sup>1</sup> of normal</td><td headers="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Free protoporphyrin / zinc-chelated protoporphyrin: ratio 90:30 to 50:50</td><td headers="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Protoporphyrins: not detectable</td><td headers="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Protoporphyrin: normal or increased</td><td headers="hd_h_epp-ar.T.biochemical_characteristics_of_1_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Plasma porphyrins: increased</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="epp-ar.TF.3.1"><p class="no_margin">Increased activity due to pathogenic "<a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a>" variants in <i>ALAS2</i> <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11</p></div></dd></dl></div></div></div><p><b>Possible additional genetic loci.</b> It is presumed that pathogenic variants at additional loci may cause the EPP <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (i.e., cutaneous photosensitivity and elevated erythrocyte protoporphyrins). Molecular epidemiology studies in the UK have identified a <i>FECH</i> or <i>ALAS2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in 94% of persons with the EPP phenotype [<a class="bk_pop" href="#epp-ar.REF.whatley.2010.642">Whatley et al 2010</a>]. Recent studies in the North American population showed that 4% of persons with the clinical phenotype and elevated protoporphyrin levels did not have a <i>FECH</i> or <i>ALAS2</i> pathogenic variant.</p></div><div id="epp-ar.Management"><h2 id="_epp-ar_Management_">Management</h2><div id="epp-ar.Evaluations_Following_Initial_Dia"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual diagnosed with erythropoietic protoporphyria (EPP), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Assessment of erythrocyte protoporphyrin levels (free and zinc-chelated), hematologic indices, and iron profile if not performed as part of diagnostic testing</div></li><li class="half_rhythm"><div>Assessment of hepatic function as well as imaging studies such as abdominal sonogram if cholelithiasis is suspected</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="epp-ar.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Acute photosensitivity.</b> Afamelanotide (Scenesse&#x000ae;), a synthetic &#x003b1;-melanocyte-stimulating hormone analog was approved for treatment of EPP by the European Medicines Agency in 2014. The drug is administered through a subcutaneously inserted bioresorbable implant which results in increased pigmentation due to an increase in eumelanin. Phase III clinical trials in the US and Europe showed an increase in pain-free sun exposure and improved quality of life in individuals with EPP. In the United States, the drug is pending FDA approval.</p><p>The phototoxic pain is not responsive to narcotic analgesics.</p><p>Current management centers on prevention of the painful attacks by avoidance of sun/light, including the long-wave ultraviolet light sunlight that passes through window glass:</p><ul><li class="half_rhythm"><div>Sun protection using protective clothing including long sleeves, gloves, and wide-brimmed hats</div></li><li class="half_rhythm"><div>Protective tinted glass for cars and windows to prevent exposure to UV light. Grey or smoke-colored filters provide only partial protection.</div></li><li class="half_rhythm"><div>Tanning products. Some tanning creams which cause increased pigmentation may be helpful. Sun creams containing a physical reflecting agent are often effective but are not cosmetically acceptable to all. Topical sunscreens are typically not useful.</div></li><li class="half_rhythm"><div>&#x003b2;-carotene. Oral Lumitene&#x02122; (120-180 mg/dL) may improve tolerance to sunlight in some patients if the dose is adjusted to maintain serum carotene levels in the range of 10-15 &#x003bc;mol/L (600-800 &#x003bc;g/dL), causing mild skin discoloration due to carotenemia. The dose of Lumitene depends on age, ranging from two to ten 30-mg capsules per day and usually started six to eight weeks before summer. The beneficial effects of &#x003b2;-carotene may involve quenching of singlet oxygen or free radicals. However, there are currently no data to support its efficacy [<a class="bk_pop" href="#epp-ar.REF.minder.2009.84">Minder et al 2009</a>].</div></li></ul><p><b>Hepatic disease.</b> Some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals develop severe liver complications that are difficult to treat, often requiring liver transplantation [<a class="bk_pop" href="#epp-ar.REF.anderson.2001">Anderson et al 2001</a>]. Hepatic complications may be accompanied by motor neuropathy.</p><ul><li class="half_rhythm"><div>Cholestyramine and other porphyrin absorbents, such as activated charcoal, may interrupt the enterohepatic circulation of protoporphyrin and promote its fecal excretion, leading to some improvement [<a class="bk_pop" href="#epp-ar.REF.mccullough.1988.177">McCullough et al 1988</a>].</div></li><li class="half_rhythm"><div>Plasmapheresis and intravenous hemin are sometimes beneficial [<a class="bk_pop" href="#epp-ar.REF.do.2002.469">Do et al 2002</a>].</div></li><li class="half_rhythm"><div>Liver transplantation has been performed as a life-saving measure in individuals with severe protoporphyric liver disease [<a class="bk_pop" href="#epp-ar.REF.mcguire.2005.1590">McGuire et al 2005</a>, <a class="bk_pop" href="#epp-ar.REF.wahlin.2011b.1021">Wahlin et al 2011b</a>]. However, transplant recipients may experience a recurrence of protoporphyric liver disease in the transplanted liver. Combined bone marrow and liver transplantation is indicated in patients with liver failure to prevent future damage to the allografts [<a class="bk_pop" href="#epp-ar.REF.rand.2006.e1896">Rand et al 2006</a>].</div></li></ul><p><b>Other.</b> Iron supplementation may be attempted in persons with anemia and abnormal iron metabolism; close monitoring is warranted. Both clinical improvement and increased photosensitivity have been reported during iron replacement therapy [<a class="bk_pop" href="#epp-ar.REF.holme.2007.1070">Holme et al 2007</a>, <a class="bk_pop" href="#epp-ar.REF.lyoumi.2007.811">Lyoumi et al 2007</a>].</p></div><div id="epp-ar.Prevention_of_Primary_Manifestati"><h3>Prevention of Primary Manifestations</h3><p>Sun avoidance is the only effective means of preventing primary manifestations.</p></div><div id="epp-ar.Prevention_of_Secondary_Complicat"><h3>Prevention of Secondary Complications</h3><p>Vitamin D supplementation is advised as patients are predisposed to vitamin D insufficiency as a result of to sun avoidance.</p><p>Immunization for hepatitis A and B is recommended.</p></div><div id="epp-ar.Surveillance"><h3>Surveillance</h3><p>Annual assessment of erythrocyte protoporphyrin levels (free and zinc-chelated), hematologic indices, and iron profile is appropriate.</p><p>Hepatic function should be monitored every six to 12 months. Hepatic imaging studies including abdominal sonogram are indicated if cholelithiasis is suspected.</p><p>Vitamin D 25-OH levels should be monitored in all patients whether or not they are receiving supplements.</p></div><div id="epp-ar.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>The following are appropriate:</p><ul><li class="half_rhythm"><div>Avoidance of sunlight and UV light</div></li><li class="half_rhythm"><div>In patients with hepatic dysfunction, avoidance of drugs that may induce cholestasis (e.g., estrogens)</div></li><li class="half_rhythm"><div>In patients with cholestatic liver failure, use of protective filters for artificial lights in the operating room to prevent phototoxic damage during procedures such as endoscopy and surgery [<a class="bk_pop" href="#epp-ar.REF.wahlin.2008.1340">Wahlin et al 2008</a>]</div></li></ul></div><div id="epp-ar.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate at-risk family members as newborns or infants in order to identify as early as possible those who would benefit from early intervention (sun protection) and future monitoring for signs of liver dysfunction.</p><p>Evaluations can include the following:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if both <i>FECH</i> pathogenic variants in the family are known</div></li><li class="half_rhythm"><div>Biochemical testing to detect markedly increased free erythrocyte protoporphyrin if the pathogenic variants in the family are not known</div></li></ul><p>See <a href="#epp-ar.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="epp-ar.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Pregnancy is not complicated by EPP. There may be some improvement in photosensitivity during pregnancy as well as a reduction in protoporphyrin levels [<a class="bk_pop" href="#epp-ar.REF.pohfitzpatrick.1997.40">Poh-Fitzpatrick 1997</a>, <a class="bk_pop" href="#epp-ar.REF.heerfordt.2016">Heerfordt &#x00026; Wulf 2016</a>].</p></div><div id="epp-ar.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Phase III clinical trials from the US and Europe with a subcutaneous insertion of a biodegradable, slow-released &#x003b1;-melanocyte-stimulating hormone analog, afamelanotide (Scenesse<sup>&#x000ae;</sup>), which increases pigmentation by increasing melanin, showed increased pain-free sun exposure and improved quality of life in those with EPP [<a class="bk_pop" href="#epp-ar.REF.harms.2009.1434">Harms et al 2009</a>, <a class="bk_pop" href="#epp-ar.REF.minder.2009.84">Minder et al 2009</a>, <a class="bk_pop" href="#epp-ar.REF.minder.2010.1591">Minder 2010</a>, <a class="bk_pop" href="#epp-ar.REF.langendonk.2015.48">Langendonk et al 2015</a>]. A long-term observational study of 115 individuals receiving Scenesse<sup>&#x000ae;</sup> for up to eight years showed improved quality of life and high compliance with the drug [<a class="bk_pop" href="#epp-ar.REF.biolcati.2015.1601">Biolcati et al 2015</a>].</p><ul><li class="half_rhythm"><div>Scenesse<sup>&#x000ae;</sup> is currently approved for use in patients with EPP in the European Union.</div></li><li class="half_rhythm"><div>In the United States, the drug is pending FDA review.</div></li></ul><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="epp-ar.Genetic_Counseling"><h2 id="_epp-ar_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="epp-ar.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Erythropoietic protoporphyria (EPP) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p><p>Note: Because of the relatively high <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency of a low-expression <i>FECH</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in some populations, and the observation of two-generation occurrence in some families, EPP was initially thought to be inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. However, molecular genetic studies have determined that the inheritance pattern is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</p></div><div id="epp-ar.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers) for either a <i>FECH</i> <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> or the common low-expression <i>FECH</i> allele.</div><ul><li class="half_rhythm"><div>Most often one parent transmits the <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> <i>FECH</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and the other transmits the common low-expression <i>FECH</i> allele to their <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child.</div></li><li class="half_rhythm"><div>In about 4% of couples, both parents transmit a <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> <i>FECH</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> to their <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child.</div></li></ul></li><li class="half_rhythm"><div>Heterozygotes (carriers) and individuals who inherit two low-expression alleles are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) and sibs who inherit two low-expression alleles are asymptomatic.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The offspring of an individual with EPP are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> <i>FECH</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> or the low-expression <i>FECH</i> allele.</div></li><li class="half_rhythm"><div>Unless an individual with EPP has children with an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual or a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> <i>FECH</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> or low-expression <i>FECH</i> allele, his/her offspring will be obligate heterozygotes (carriers) for a loss-of-function <i>FECH</i> allele or the low-expression <i>FECH</i> allele. Note: An individual who inherits two copies of the common low-expression <i>FECH</i> allele does not manifest EPP.</div></li></ul><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>&#x02019;s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a loss of function <i>FECH</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> or low-expression <i>FECH</i> allele.</p></div><div id="epp-ar.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk family members requires prior identification of the <i>FECH</i> pathogenic variants in the family.</p><p>Biochemical testing is not used for <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> detection.</p></div><div id="epp-ar.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#epp-ar.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="epp-ar.Prenatal_Testing_and_Preimplantat"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>FECH</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Biochemical testing is not used for <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a>.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="epp-ar.Resources"><h2 id="_epp-ar_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>British Porphyria Association</b></div><div>United Kingdom</div><div><b>Phone:</b> 0300 30 200 30</div><div><b>Email:</b> helpline@porphyria.org.uk</div><div><a href="http://www.porphyria.org.uk/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porphyria.org.uk</a></div></li><li class="half_rhythm"><div><b>Canadian Association for Porphyria/Association Canadienne de Porphyrie</b></div><div>Canada</div><div><a href="http://canadianassociationforporphyria.ca/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.canadianassociationforporphyria.ca</a></div></li><li class="half_rhythm"><div><b>Find a Porphyria Expert</b></div><div>American Porphyria Foundation</div><div><a href="https://www.porphyriafoundation.org/for-patients/porphyria-experts/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porphyriafoundation.org/for-patients/porphyria-experts</a></div></li><li class="half_rhythm"><div><b>American Porphyria Foundation (APF)</b></div><div>915 St. Elmo Avenue</div><div>Suite 200</div><div>Bethesda MD 20814</div><div><b>Phone:</b> 866-APF-3635 (toll-free); 301-347-7166</div><div><b>Email:</b> porphyrus@porphyriafoundation.com</div><div><a href="https://www.porphyriafoundation.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porphyriafoundation.org</a></div></li><li class="half_rhythm"><div><b>European Porphyria Network</b></div><div><b>Email:</b> contact@porphyria.eu</div><div><a href="http://porphyria.eu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">porphyria.eu</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=acuteintermittentporphyria;jsessionid=D4E2E078605EC9CE8599D96BB81EBC0E" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Porphyria</a></div></li><li class="half_rhythm"><div><b>Swedish Porphyria Patients' Association</b></div><div>Karolinska Universitetssjukhuset</div><div>Huddinge M 96</div><div>Stockholm Stockholms Lan SE-141 86</div><div>Sweden</div><div><b>Phone:</b> +46 8 711 56 09 </div><div><b>Email:</b> porfyrisjukdomar@gmail.com</div><div><a href="http://www.porfyri.se" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porfyri.se</a></div></li></ul></div><div id="epp-ar.Molecular_Genetics"><h2 id="_epp-ar_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="epp-ar.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Erythropoietic Protoporphyria, Autosomal Recessive: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK100826/table/epp-ar.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epp-ar.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_epp-ar.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_epp-ar.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_epp-ar.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_epp-ar.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_epp-ar.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_epp-ar.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_epp-ar.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2235" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>FECH</i></a></td><td headers="hd_b_epp-ar.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2235" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">18q21<wbr style="display:inline-block"></wbr>​.31</a></td><td headers="hd_b_epp-ar.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P22830" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Ferrochelatase, mitochondrial</a></td><td headers="hd_b_epp-ar.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/FECH" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FECH database</a></td><td headers="hd_b_epp-ar.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FECH" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FECH</a></td><td headers="hd_b_epp-ar.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FECH[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FECH</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="epp-ar.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="epp-ar.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Erythropoietic Protoporphyria, Autosomal Recessive (<a href="/omim/177000,612386" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK100826/table/epp-ar.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epp-ar.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/177000" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">177000</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/612386" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">612386</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FERROCHELATASE; FECH</td></tr></tbody></table></div></div><p><b>Gene structure.</b> Two transcript variants encoding different <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> have been found for <i>FECH</i>. The transcript variant <a href="/nuccore/NM_000140.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000140.3</a> has 11 exons. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK100826/#epp-ar.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Nearly 200 pathogenic variants [<a class="bk_pop" href="#epp-ar.REF.stenson.2017.665">Stenson et al 2017</a>, <a href="http://www.hgmd.cf.ac.uk/ac/index.php" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGMD</a>] have been identified in <i>FECH</i>, many of which result in an unstable or absent enzyme. Loss-of-function variants include <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> and <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants, small deletions, and insertions. The common low-expression <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> c.315-48T&#x0003e;C creates a cryptic splice acceptor site and decreases the abundance of the normal transcript to about 25% of normal levels. The aberrantly spliced <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> is degraded by a nonsense-mediated decay mechanism. This variant has an <a class="def" href="/books/n/gene/glossary/def-item/allele-frequency/">allele frequency</a> of about 10% in healthy individuals of European descent [<a class="bk_pop" href="#epp-ar.REF.gouya.1999.2105">Gouya et al 1999</a>, <a class="bk_pop" href="#epp-ar.REF.gouya.2002.27">Gouya et al 2002</a>].</p><div id="epp-ar.T.selected_fech_pathogenic_varian" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Selected <i>FECH</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK100826/table/epp-ar.T.selected_fech_pathogenic_varian/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epp-ar.T.selected_fech_pathogenic_varian_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_epp-ar.T.selected_fech_pathogenic_varian_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Conventional Nomenclature&#x000a0;<sup>1</sup>)</th><th id="hd_h_epp-ar.T.selected_fech_pathogenic_varian_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_epp-ar.T.selected_fech_pathogenic_varian_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_epp-ar.T.selected_fech_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.315-48T&#x0003e;C&#x000a0;<sup>2</sup><br />(IVS3-48T&#x0003e;C)</td><td headers="hd_h_epp-ar.T.selected_fech_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Aberrant <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 4</td><td headers="hd_h_epp-ar.T.selected_fech_pathogenic_varian_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000140.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000140<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/NP_000131.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000131<wbr style="display:inline-block"></wbr>​.2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="epp-ar.TF.4.1"><p class="no_margin">Conventional variant nomenclature: Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>)</p></div></dd><dt>2. </dt><dd><div id="epp-ar.TF.4.2"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The normal gene encodes an enzyme of 423 amino acids (<a href="/protein/NP_000131.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000131.2</a>), including a 54-residue polypeptide for localization in the mitochondrion.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants in <i>FECH</i> result in either a nonfunctional or a partially functional enzyme.</p><p>About 96% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are compound heterozygotes for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> resulting in markedly decreased ferrochelatase activity and a second low-expression mutated <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (c.315-48T&#x0003e;C) resulting in residual ferrochelatase activity. In about 4% of families with EPP, two pathogenic <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> <i>FECH</i> variants are inherited, resulting in very low levels of functional ferrochelatase [<a class="bk_pop" href="#epp-ar.REF.whatley.2010.642">Whatley et al 2010</a>].</p></div><div id="epp-ar.References"><h2 id="_epp-ar_References_">References</h2><div id="epp-ar.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.anderson.2001">Anderson KE, Sassa S, Bishop DF, Desnick RJ: Disorders of heme biosynthesis: X-linked sideroblastic anemias and the porphyrias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Vogelstein B, eds. <em>The Metabolic and Molecular Basis of Inherited Disease</em>. 8 ed. New York, NY: McGraw-Hill; 2001:2991-3062.</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.aplin.2001.1647">Aplin C, Whatley SD, Thompson P, Hoy T, Fisher P, Singer C, Lovell CR, Elder GH. Late-onset erythropoietic porphyria caused by a chromosome 18q deletion in erythroid cells. <span><span class="ref-journal">J Invest Dermatol. </span>2001;<span class="ref-vol">117</span>:1647–9.</span> [<a href="/pubmed/11886534" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11886534</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.balwani.2013.26">Balwani M, Doheny D, Bishop DF, Nazarenko I, Yasuda M, Dailey HA, Anderson KE, Bissell DM, Bloomer J, Bonkovsky HL, Phillips JD, Liu L, Desnick RJ., Porphyrias Consortium of the National Institutes of Health Rare Diseases Clinical Research Network.  Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria. <span><span class="ref-journal">Mol Med. </span>2013;<span class="ref-vol">19</span>:26–35.</span> [<a href="/pmc/articles/PMC3646094/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3646094</span></a>] [<a href="/pubmed/23364466" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23364466</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.balwani.2017.789">Balwani M, Naik H, Anderson KE, Bissell DM, Bloomer J, Bonkovsky HL, Phillips JD, Overbey JR, Wang B, Singal AK, Liu LU, Desnick RJ. Clinical, biochemical, and genetic characterization of North American patients with erythropoietic protoporphyria and X-linked protoporphyria. <span><span class="ref-journal">JAMA Dermatol. </span>2017;<span class="ref-vol">153</span>:789–96.</span> [<a href="/pmc/articles/PMC5710403/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5710403</span></a>] [<a href="/pubmed/28614581" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28614581</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.blagojevic.2010.743">Blagojevic D, Schenk T, Haas O, Zierhofer B, Konnaris C, Trautinger F. Acquired erythropoietic protoporphyria. <span><span class="ref-journal">Ann Hematol. </span>2010;<span class="ref-vol">89</span>:743–4.</span> [<a href="/pubmed/19902211" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19902211</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.bloomer.1988.402">Bloomer JR. The liver in protoporphyria. <span><span class="ref-journal">Hepatology. </span>1988;<span class="ref-vol">8</span>:402–7.</span> [<a href="/pubmed/3281889" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3281889</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.biolcati.2015.1601">Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. <span><span class="ref-journal">Br J Dermatol. </span>2015;<span class="ref-vol">172</span>:1601–12.</span> [<a href="/pubmed/25494545" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25494545</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.brancaleoni.2016.20">Brancaleoni V, Balwani M, Granata F, Graziadei G, Missineo P, Fiorentino V, Fustinoni S, Cappellini MD, Naik H, Desnick RJ, Di Pierro E. X-chromosomal inactivation directly influences the phenotypic manifestation of X-linked protoporphyria. <span><span class="ref-journal">Clin Genet. </span>2016;<span class="ref-vol">89</span>:20–6.</span> [<a href="/pmc/articles/PMC4512933/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4512933</span></a>] [<a href="/pubmed/25615817" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25615817</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.do.2002.469">Do KD, Banner BF, Katz E, Szymanski IO, Bonkovsky HL. Benefits of chronic plasmapheresis and intravenous heme-albumin in erythropoietic protoporphyria after orthotopic liver transplantation. <span><span class="ref-journal">Transplantation. </span>2002;<span class="ref-vol">73</span>:469–72.</span> [<a href="/pubmed/11884947" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11884947</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.gouya.1999.2105">Gouya L, Puy H, Lamoril J, Da Silva V, Grandchamp B, Nordmann Y, Deybach JC. Inheritance in erythropoietic protoporphyria: a common wild-type ferrochelatase allelic variant with low expression accounts for clinical manifestation. <span><span class="ref-journal">Blood. </span>1999;<span class="ref-vol">93</span>:2105–10.</span> [<a href="/pubmed/10068685" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10068685</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.gouya.2002.27">Gouya L, Puy H, Robreau AM, Bourgeois M, Lamoril J, Da Silva V, Grandchamp B, Deybach JC. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. <span><span class="ref-journal">Nat Genet. </span>2002;<span class="ref-vol">30</span>:27–8.</span> [<a href="/pubmed/11753383" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11753383</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.harms.2009.1434">Harms JH, Lautenschlager S, Minder CE, Minder EI. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. <span><span class="ref-journal">Photochem Photobiol. </span>2009;<span class="ref-vol">85</span>:1434–9.</span> [<a href="/pubmed/19656325" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19656325</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.heerfordt.2016">Heerfordt IM, Wulf HC. Patients with erythropoietic protoporphyria have reduced erythrocyte protoporphyrin IX from early in pregnancy. <span><span class="ref-journal">Br J Dermatol. </span>2016 Dec 10;</span> [<a href="/pubmed/27943252" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27943252</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.holme.2008.211">Holme SA, Anstey AV, Badminton MN, Elder GH. Serum 25-hydroxyvitamin D in erythropoietic protoporphyria. <span><span class="ref-journal">Br J Dermatol. </span>2008;<span class="ref-vol">159</span>:211.</span> [<a href="/pubmed/18476956" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18476956</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.holme.2006.574">Holme SA, Anstey AV, Finlay AY, Elder GH, Badminton MN. Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life. <span><span class="ref-journal">Br J Dermatol. </span>2006;<span class="ref-vol">155</span>:574–81.</span> [<a href="/pubmed/16911284" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16911284</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.holme.2007.1070">Holme SA, Thomas CL, Whatley SD, Bentley DP, Anstey AV, Badminton MN. Symptomatic response of erythropoietic protoporphyria to iron supplementation. <span><span class="ref-journal">J Am Acad Dermatol. </span>2007;<span class="ref-vol">56</span>:1070–2.</span> [<a href="/pubmed/17504727" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17504727</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.holme.2009.599">Holme SA, Whatley SD, Roberts AG, Anstey AV, Elder GH, Ead RD, Stewart MF, Farr PM, Lewis HM, Davies N, White MI, Ackroyd RS, Badminton MN. Seasonal palmar keratoderma in erythropoietic protoporphyria indicates autosomal recessive inheritance. <span><span class="ref-journal">J Invest Dermatol. </span>2009;<span class="ref-vol">129</span>:599–605.</span> [<a href="/pubmed/18787536" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18787536</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.langendonk.2015.48">Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neumann NJ, Parker C, Phillips JD, Lim HW, Hamzavi I, Deybach JC, Kauppinen R, Rhodes LE, Frank J, Murphy GM, Karstens FP, Sijbrands EJ, de Rooij FW, Lebwohl M, Naik H, Goding CR, Wilson JH, Desnick RJ. Afamelanotide for erythropoietic protoporphyria. <span><span class="ref-journal">N Engl J Med. </span>2015;<span class="ref-vol">373</span>:48–59.</span> [<a href="/pmc/articles/PMC4780255/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4780255</span></a>] [<a href="/pubmed/26132941" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26132941</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.lyoumi.2007.811">Lyoumi S, Abitbol M, Andrieu V, Henin D, Robert E, Schmitt C, Gouya L, de Verneuil H, Deybach JC, Montagutelli X, Beaumont C, Puy H. Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice. <span><span class="ref-journal">Blood. </span>2007;<span class="ref-vol">109</span>:811–8.</span> [<a href="/pubmed/17003376" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17003376</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.mccullough.1988.177">McCullough AJ, Barron D, Mullen KD, Petrelli M, Park MC, Mukhtar H, Bickers DR. Fecal protoporphyrin excretion in erythropoietic protoporphyria: effect of cholestyramine and bile acid feeding. <span><span class="ref-journal">Gastroenterology. </span>1988;<span class="ref-vol">94</span>:177–81.</span> [<a href="/pubmed/3335288" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3335288</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.mcguire.2005.1590">McGuire BM, Bonkovsky HL, Carithers RL Jr, Chung RT, Goldstein LI, Lake JR, Lok AS, Potter CJ, Rand E, Voigt MD, Davis PR, Bloomer JR. Liver transplantation for erythropoietic protoporphyria liver disease. <span><span class="ref-journal">Liver Transpl. </span>2005;<span class="ref-vol">11</span>:1590–6.</span> [<a href="/pubmed/16315313" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16315313</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.m_ndez.2009.1330">M&#x000e9;ndez M, Poblete-Guti&#x000e9;rrez P, Mor&#x000e1;n-Jim&#x000e9;nez MJ, Rodriguez ME, Garrido-Astray MC, Fontanellas A, Frank J, de Salamanca RE. A homozygous mutation in the ferrochelatase gene underlies erythropoietic protoporphyria associated with palmar keratoderma. <span><span class="ref-journal">Br J Dermatol. </span>2009;<span class="ref-vol">160</span>:1330–4.</span> [<a href="/pubmed/19298273" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19298273</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.minder.2010.1591">Minder EI. Afamelanotide, an agonistic analog of &#x003b1;-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria. <span><span class="ref-journal">Expert Opin Investig Drugs. </span>2010;<span class="ref-vol">19</span>:1591–602.</span> [<a href="/pubmed/21073357" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21073357</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.minder.2002.91">Minder EI, Gouya L, Schneider-Yin X, Deybach JC. A genotype-phenotype correlation between null-allele mutations in the ferrochelatase gene and liver complication in patients with erythropoietic protoporphyria. <span><span class="ref-journal">Cell Mol Biol (Noisy-le-grand). </span>2002;<span class="ref-vol">48</span>:91–6.</span> [<a href="/pubmed/11929053" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11929053</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.minder.2010.1349">Minder EI, Schneider-Yin X, Mamet R, Horev L, Neuenschwander S, Baumer A, Austerlitz F, Puy H, Schoenfeld N. A homoallelic FECH mutation in a patient with both erythropoietic protoporphyria and palmar keratoderma. <span><span class="ref-journal">J Eur Acad Dermatol Venereol. </span>2010;<span class="ref-vol">24</span>:1349–53.</span> [<a href="/pubmed/20337824" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20337824</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.minder.2009.84">Minder EI, Schneider-Yin X, Steurer J, Bachmann LM. A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria. <span><span class="ref-journal">Cell Mol Biol (Noisy-le-grand). </span>2009;<span class="ref-vol">55</span>:84–97.</span> [<a href="/pubmed/19268006" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19268006</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.pohfitzpatrick.1997.40">Poh-Fitzpatrick MB. Human protoporphyria: reduced cutaneous photosensitivity and lower erythrocyte porphyrin levels during pregnancy. <span><span class="ref-journal">J Am Acad Dermatol. </span>1997;<span class="ref-vol">36</span>:40–3.</span> [<a href="/pubmed/8996259" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8996259</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.rand.2006.e1896">Rand EB, Bunin N, Cochran W, Ruchelli E, Olthoff KM, Bloomer JR. Sequential liver and bone marrow transplantation for treatment of erythropoietic protoporphyria. <span><span class="ref-journal">Pediatrics. </span>2006;<span class="ref-vol">118</span>:e1896–9.</span> [<a href="/pubmed/17074841" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17074841</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.sarkany.2006.464">Sarkany RP, Ross G, Willis F. Acquired erythropoietic protoporphyria as a result of myelodysplasia causing loss of chromosome 18. <span><span class="ref-journal">Br J Dermatol. </span>2006;<span class="ref-vol">155</span>:464–6.</span> [<a href="/pubmed/16882191" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16882191</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.schneideryin.2000.719">Schneider-Yin X, Gouya L, Meier-Weinand A, Deybach JC, Minder EI. New insights into the pathogenesis of erythropoietic protoporphyria and their impact on patient care. <span><span class="ref-journal">Eur J Pediatr. </span>2000;<span class="ref-vol">159</span>:719–25.</span> [<a href="/pubmed/11039124" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11039124</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.spelt.2010.s1">Spelt JM, de Rooij FW, Wilson JH, Zandbergen AA. Vitamin D deficiency in patients with erythropoietic protoporphyria. <span><span class="ref-journal">J Inherit Metab Dis. </span>2010;<span class="ref-vol">33</span>:S1–4.</span> [<a href="/pubmed/24137761" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24137761</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.stenson.2017.665">Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas NS, Cooper DN. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. <span><span class="ref-journal">Hum Genet. </span>2017;<span class="ref-vol">136</span>:665–77.</span> [<a href="/pmc/articles/PMC5429360/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5429360</span></a>] [<a href="/pubmed/28349240" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28349240</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.wahlin.2011a.278">Wahlin S, Floderus Y, St&#x000e5;l P, Harper P. Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics. <span><span class="ref-journal">J Intern Med. </span>2011a;<span class="ref-vol">269</span>:278–88.</span> [<a href="/pubmed/20412370" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20412370</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.wahlin.2008.1340">Wahlin S, Srikanthan N, Hamre B, Harper P, Brun A. Protection from phototoxic injury during surgery and endoscopy in erythropoietic protoporphyria. <span><span class="ref-journal">Liver Transpl. </span>2008;<span class="ref-vol">14</span>:1340–6.</span> [<a href="/pubmed/18756472" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18756472</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.wahlin.2011b.1021">Wahlin S, Stal P, Adam R, Karam V, Porte R, Seehofer D, Gunson BK, Hillings&#x000f8; J, Klempnauer JL, Schmidt J, Alexander G, O'Grady J, Clavien PA, Salizzoni M, Paul A, Rolles K, Ericzon BG, Harper P., European Liver and Intestine Transplant Association.  Liver transplantation for erythropoietic protoporphyria in Europe. <span><span class="ref-journal">Liver Transpl. </span>2011b;<span class="ref-vol">17</span>:1021–6.</span> [<a href="/pubmed/21604355" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21604355</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.whatley.2008.408">Whatley SD, Ducamp S, Gouya L, Grandchamp B, Beaumont C, Badminton MN, Elder GH, Holme SA, Anstey AV, Parker M, Corrigall AV, Meissner PN, Hift RJ, Marsden JT, Ma Y, Mieli-Vergani G, Deybach JC, Puy H. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. <span><span class="ref-journal">Am J Hum Genet. </span>2008;<span class="ref-vol">83</span>:408–14.</span> [<a href="/pmc/articles/PMC2556430/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2556430</span></a>] [<a href="/pubmed/18760763" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18760763</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.whatley.2007.2790">Whatley SD, Mason NG, Holme SA, Anstey AV, Elder GH, Badminton MN. Gene dosage analysis identifies large deletions of the FECH gene in 10% of families with erythropoietic protoporphyria. <span><span class="ref-journal">J Invest Dermatol. </span>2007;<span class="ref-vol">127</span>:2790–4.</span> [<a href="/pubmed/17597821" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17597821</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.whatley.2010.642">Whatley SD, Mason NG, Holme SA, Anstey AV, Elder GH, Badminton MN. Molecular epidemiology of erythropoietic protoporphyria in the united kingdom. <span><span class="ref-journal">Br J Dermatol. </span>2010;<span class="ref-vol">162</span>:642–6.</span> [<a href="/pubmed/20105171" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20105171</span></a>]</div></li></ul></div><div id="epp-ar.Suggested_Reading"><h3>Suggested Reading</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.puy.2010.924">Puy H, Gouya L, Deybach JC. Porphyrias. <span><span class="ref-journal">Lancet. </span>2010;<span class="ref-vol">375</span>:924–37.</span> [<a href="/pubmed/20226990" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20226990</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-ar.REF.layer.2010.1137">Layer G, Reichelt J, Jahn D, Heinz DW. Structure and function of enzymes in heme biosynthesis. <span><span class="ref-journal">Protein Sci. </span>2010;<span class="ref-vol">19</span>:1137–61.</span> [<a href="/pmc/articles/PMC2895239/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2895239</span></a>] [<a href="/pubmed/20506125" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20506125</span></a>]</div></li></ul></div></div><div id="epp-ar.Chapter_Notes"><h2 id="_epp-ar_Chapter_Notes_">Chapter Notes</h2><div id="epp-ar.Acknowledgments"><h3>Acknowledgments</h3><p>The EPP contribution to <i>GeneReviews</i> was supported in part by the Porphyrias Consortium of the NIH-supported <a href="http://www.rarediseasesnetwork.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Rare Diseases Clinical Research Network</a> (NIH grant: 5 U54 DK083909), including:</p><ul><li class="half_rhythm"><div>Dr Karl Anderson, University of Texas Medical Branch, Galveston, TX</div></li><li class="half_rhythm"><div>Dr Montgomery Bissell, University of California, San Francisco, CA</div></li><li class="half_rhythm"><div>Dr Herbert Bonkovsky, Carolinas Medical Center, Charlotte, NC</div></li><li class="half_rhythm"><div>Dr John Phillips, University of Utah School of Medicine, Salt Lake City, UT</div></li></ul></div><div id="epp-ar.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>7 September 2017 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>16 October 2014 (me) Comprehensive updated posted live</div></li><li class="half_rhythm"><div>27 September 2012 (me) Review posted live</div></li><li class="half_rhythm"><div>10 April 2012 (rd) Original submission</div></li></ul></div></div><div><dl class="temp-labeled-list small"><dt>*</dt><dd><div id="epp-ar.Tb.an4"><p class="no_top_margin">See Chapter Notes, <a href="#epp-ar.Acknowledgments">Acknowledgments</a>.</p></div></dd></dl></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK100826</span><span class="label">PMID: <a href="/pubmed/23016163" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">23016163</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/ea2/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/tef-ov/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK100826&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK100826/?report=reader">PubReader</a></li><li><a href="/books/NBK100826/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK100826" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK100826" style="display:none" title="Cite this Page"><div class="bk_tt">Balwani M, Bloomer J, Desnick R; Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network. Erythropoietic Protoporphyria, Autosomal Recessive. 2012 Sep 27 [Updated 2017 Sep 7]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK100826/pdf/Bookshelf_NBK100826.pdf">PDF version of this page</a> (450K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#epp-ar.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#epp-ar.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#epp-ar.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#epp-ar.Genetically_Related_Allelic_Disor" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#epp-ar.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#epp-ar.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#epp-ar.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#epp-ar.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#epp-ar.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#epp-ar.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#epp-ar.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2235[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FECH</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK100826+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=2977528" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=2977528" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=2977528" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=2977528" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23409301" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Protoporphyria</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Protoporphyria<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Balwani M, Desnick R, Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24027798" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Erythropoietic Porphyria</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Erythropoietic Porphyria<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Erwin A, Balwani M, Desnick RJ, Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/19744342" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Erythropoietic protoporphyria.</a><span class="source">[Orphanet J Rare Dis. 2009]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Erythropoietic protoporphyria.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lecha M, Puy H, Deybach JC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Orphanet J Rare Dis. 2009 Sep 10; 4:19. Epub 2009 Sep 10.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23409300" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Variegate Porphyria</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Variegate Porphyria<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Singal AK, Anderson KE. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23236641" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hereditary Coproporphyria</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hereditary Coproporphyria<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wang B, Bissell DM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=23016163" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=23016163" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0414e4dde0891169e928fa">Erythropoietic Protoporphyria, Autosomal Recessive - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Erythropoietic Protoporphyria, Autosomal Recessive - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:03:16-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE882999E0412F910000000000DA0056&amp;ncbi_session=CE882999E0414E31_0218SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK100826%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK100826&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK100826/&amp;ncbi_pagename=Erythropoietic Protoporphyria, Autosomal Recessive - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE882999E0414E31_0218SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>